Navigation Links
IAEA conference to focus on new techniques in cancer treatment
Date:4/23/2009

Vienna, 21 April 2009 | About 400 cancer therapy specialists from 100 countries (96 IAEA Member States, 4 non-Member States) will meet next week in Vienna at an IAEA event to discuss modern techniques in radiation treatment of cancer.

The three-day International Conference on Advances in Radiation Oncology (ICARO) will start on Monday, 27 April, in the new Conference Building M of the Vienna International Center.

All sessions of the event are open to the media.

Radiotherapy will be the main focus of the conference, as it remains one of the most commonly used methods of cancer treatment. ICARO will concentrate on implementation of modern treatment techniques, which improve the chance of cancer cure whilst reducing the risk of serious side effects and complications.

ICARO will include many participants from low and middle-income countries, which are often under represented in such venues. A total of 24 major national and international organizations in the field of radiation oncology will also take part in the conference.

More information and the programme of the Conference is available on http://www-pub.iaea.org/MTCD/Meetings/Announcements.asp?ConfID=35265

Journalists wishing to cover the event can register online or e-mail Al Sinoy or call [43-1] 2600-21276.

Individual interviews can be arranged through IAEA Press Office.

BACKGROUND:

The IAEA has a central and pivotal role in convening this meeting as a unique international forum which enables both the developed and developing countries to impact and improve the care of cancer patients by sharing and learning from each other's experience.

Cancer is rapidly becoming a major health problem globally, both in developed and developing countries. Despite the increase in the number of cancer patients, advanced treatments are expensive and the resources available in health care are limited. Although a cancer itself is a global issue, its management is especially critical in developing countries, which are in the process of developing strategies and programmes for treating cancer.

The main focus of ICARO meeting will be Radiotherapy, which is one of the most commonly used methods of cancer treatment. Radiotherapy has also a crucial role in reducing the symptoms of cancer, such as pain, and in improving the quality of life of cancer sufferers who cannot be cured. It is an important and cost-effective component of cancer management, but requires sophisticated equipment and highly trained personnel.

Acquiring new technology and implementing it can be expensive both in terms of improving infrastructure and training of human resources needed to support it. There will never be an over-abundance of resources to support acquiring new technology, so a broad perspective strategy for implementing the technology is essential for assessing its impact.

The conference will also discuss the requirements of advanced technologies in terms of training and equipment and their applicability in different environments.


'/>"/>

Contact: IAEA Press Office
press@iaea.org
43-126-002-1273
International Atomic Energy Agency
Source:Eurekalert

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... Louisiana (PRWEB) , ... April 29, 2017 , ... ... Brookshire’s Grocery Company to the list of fine retailers selling biodegradable, hanging flushable ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more ...
(Date:4/28/2017)... ... 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses the case ... help of a weight loss surgery. The woman, declaring “I will not hate my body ... following her dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers ...
(Date:4/28/2017)... , ... April 28, 2017 , ... It's not always ... a number of illnesses that are unclear as to whether or not they are ... Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the matter. ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” ... Water, Global Climate Change and Your Health on Voice America sponsored by Nature’s ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities ... to their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming ... provides an in-depth assessment of the current trends in ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive Pharmaceutical ... today announced positive preclinical results demonstrating anti-fibrotic ... for non-alcoholic steatohepatitis (NASH), in an additional ... NV556 has previously shown similar anti-fibrotic ... Today, NeuroVive,s scientists present novel data demonstrating ...
Breaking Medicine Technology: